Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA)

NCT00787917 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00787917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00787917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA)
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Terminated
Start date
November 30, 2008
Completion date
July 31, 2010
Enrollment
14 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

allergic bronchopulmonary aspergillosis, cystic fibrosis